Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphomaJennifer L. Crombie, Gary Simmons, Kevin Tang et al.|Blood Advances|2021Cited by 36
A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphomaAndrew Looka, Caron A. Jacobson, David Qualls et al.|Blood Advances|2024Cited by 30
Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy.Lindsey Fitzgerald, Boyu Hu, Adam S. Kittai et al.|Journal of Clinical Oncology|2020Cited by 19
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy RecipientsMuneerah M Aleissa, Amy C Sherman, Jessica S Little et al.|Transplantation and Cellular Therapy|2023Cited by 15
Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapyJennifer L. Crombie, Brian Hess, Caron A. Jacobson et al.|Haematologica|2023Cited by 6